Best Genomics Companies in Arizona, United States
The 32 best Genomics companies in Arizona, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Accelerate Diagnostics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Arizona
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3dbiosurfaces Developer of a multiplex microarray plate | — | — | Deadpooled | Barry Beroth Co-Founder & CEO | — | — | 3 patents High-surface-area microarray substrates for enhanced biomolecule capture and retention | — |
| 2 | AexeRNA Developer of mRNA therapeutics and lipid nanoparticle delivery technologies | — | — | Funding Raised | Drew Weissman Co-Founder | 4 | — | — | — |
| 3 | AllTests Online Provider of personal DNA, paternity, STD, and drug tests | — | — | Unfunded | Michael Brand Owner | — | — | — | — |
| 4 | Applied Micro Arrays Contract manufacturer of custom nucleic acid and protein microarrays | — | — | Acqui-Hired | — | 4 | — | — | — |
| 5 | ARCTERUS Provider of a diagnostic platform for medical professionals and clinicians | — | — | Unfunded | Jake Crown CEO | — | — | — | — |
| 6 | Canary AI-based personalized cancer diagnostics and treatment solutions | — | — | Unfunded | Harry Lander CEO | — | UbuntuSvelteAstro+11 | — | — |
| 7 | DNASpectrum Provider of DNA sequencing services | — | — | Deadpooled | Paul Yates Founder & CEO | — | — | — | — |
| 8 | Dropworks Manufacturer of digital PCR instruments for laboratory use | — | — | Acquired | Chris Perkins CEO | 48 | — | 53 patents Continuous emulsion manufacturing and narrow conduit flow control for pharma/chemical processes | — |
Top 12 Genomics companies in Arizona
#1
Seed · Scottsdale, Arizona · founded 2018 · 7 employees$1.2Mraised▾
Developer of gene-editing tool for dogs to fight against cancer. The company helps in editing the immune T cells of the dog with Chimeric antigen receptors (CAR) to form CAR T cells, which target the B-cell lymphoma in canine cancer.
- Oct 2023Grant (prize money)$973.9K
- 2023Grant (prize money)$225K
- Mar 2022Grant (prize money)$337.4K
- Apr 2021Seed$270.1K
#2
Public · Tucson, Arizona · founded 1987 · 197 employees$366.3Mraised▾
Developer of diagnostic devices and test kits for the antibiotic resistant infections. The company's products include Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections.
- Mar 2021Post IPO$32M
- Aug 2019Post IPO$1000K
- Mar 2018Post IPO$171.5M
- May 2017Post IPO$79.3M
#3
Public · Tucson, Arizona · founded 1997 · 47 employees$47.3Mraised▾
Developer of diagnostics and targeted therapeutics across a variety of disease areas. The company is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA, and mRNA measurement for translational medicine and diagnostic applications. Their automated HTG Edge platform is designed to quickly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies. Also offers services (VERI/O Laboratory Services ) such as retrospective sample processing, pilot studies, custom assay development, disease-specific validation studies, and molecular profiling studies
- Jun 2020Post IPO$3M
- Sep 2019Post IPO$3.5M
- Jan 2018Post IPO$2.2M
- Aug 2014Conventional Debt$16M
#4
Series B · Tucson, Arizona · founded 2014 · 31 employees$11.6Mraised▾
PathogenDX provides DNA-based pathogen testing kits. They offer Delivering Disruptive Testing Technology to the botanicals, food, and agriculture industries. The company focuses on food and agricultural microbial testing, cannabis testing, and botanical testing.
- Aug 2020Grant (prize money)—
- Aug 2020Grant (prize money)$1.1M
- Sep 2019Series B$7.5M
- Jul 2018Series A$3.4M
#5
Acquired · Phoenix, Arizona · founded 2014 · 6 employees$1.3Mraised▾
Online casino and sports betting platform with diverse gaming options. This platform provides a wide array of casino games, including slots, live dealer options, poker, blackjack, baccarat, keno, and scratch cards. It also offers sports betting opportunities on live events. The platform supports multiple languages and currencies to cater to a global audience. It facilitates secure transactions through various payment systems, including bank cards, e-wallets, and cryptocurrencies. The platform prioritizes user experience with a user-friendly interface and customer support channels like live chat and Telegram. It is a comprehensive online gaming destination, offering both traditional casino experiences and modern sports wagering. The platform is known for its bonuses and promotions, aiming to enhance user engagement and satisfaction.
- Sep 2021Seed$523.4K
- Jul 2017Seed$750K
- Jan 2016Grant (prize money)$226.3K
#6
Acquired · Phoenix, Arizona · founded 2012 · 23 employees$11Mraised▾
Eradicating cancer through prevention, early detection, and personalized therapy guidance. The company is dedicated to fighting cancer every step of the way, bringing clarity to patients, providers, doctors, researchers, and caregivers. They offer tests that explore hereditary risks, screen for cancer's presence, and examine genomic alterations to guide treatment. Their focus is on improving patient outcomes through life-changing science, deep expertise, strong collaboration, and rigorous research. They are committed to making a lasting, positive impact on people's lives by providing innovative products and services in cancer prevention, screening, and therapy guidance. They offer login for patients and providers. They are involved in clinical studies and publications.
- May 2019Series B—
- Nov 2018Series B$11M
#7
Acquired · Tucson, Arizona · founded 2006 · 23 employees$15.9Mraised▾
Developer of autologous cell therapies to enhance immune response for infectious diseases. The company's focus is on the development of AIDS therapies by targeting the CC5 proteins that are used by HIV to infect T-cells. It has been developed by the patient's own stem cells to reduce the production of CC5 proteins, in addition to modifying mature T-cells to block HIV entry.
- May 2015Series B$15.9M
#8
Series A · Tempe, Arizona · founded 2007 · 18 employees$3.8Mraised▾
Early cancer detection through advanced nano-biotechnology and genome sequencing. The company focuses on developing innovative nano-biotechnology platforms and machine learning tools for high-accuracy, early-stage disease diagnostics. They aim to extract systems-scale information from complex disease biology to identify and detect disease-specific molecular biomarkers at pre-symptomatic stages. Their technology includes exponential nanosensors (FDEC) and advanced 3D nanopore-transistor devices for rapid, low-cost genome sequencing. This enables early cancer detection through simple blood tests, potentially eliminating the need for biopsies. The goal is to enable preemptive medicine by facilitating early personalized therapeutic intervention, ultimately improving patient outcomes and reducing healthcare costs. This is a B2B tech company.
- Sep 2018Series A$3.3M
- Apr 2016Seed$427K
#9
Funding Raised · Phoenix, Arizona · founded 2015 · 3 employees$1.1Mraised▾
Provider of technology for gene expression analysis of tumor samples. It's platform technology LightStream FloCell uses microfluidics and advanced analytic algorithms to create in situ expression profiles for tumor samples called the Tumor Heterogeneity Profile (THP). The THP enables researchers to study gene expression profiles in the context of intact tissue morphology.
- Feb 2018Grant (prize money)$892.1K
- Dec 2016Grant (prize money)$213.9K
- Mar 2016Grant (prize money)$30K
#10
Seed · Scottsdale, Arizona · founded 2020 · 10 employees$200Kraised▾
Developer of diagnosis & treatment solutions of diseases by using genome data science. It provides a genome platform combination of genomics, artificial intelligence, and computational biology to address the traditional pathogen tests of multiple therapeutic conditions. It also provides solutions for microbiome characterization, immune characterization, and more.
- Dec 2020Seed$200K
#11
Seed · Tucson, Arizona · founded 2004$837.4Kraised▾
Provider of micro array technologies to bypass DNA purification and quantitation. The company offers HLA Chip technology based on HLA typing for tissue transplantation and stem cell therapeutics, as well as based on HLA analysis for vaccine development, personalized vaccine delivery, personalized treatment for autoimmune diseases, and personalized treatment of microbial infection.
- Jun 2013Seed$837.4K
#12
Seed · Scottsdale, Arizona · founded 2016$100Kraised▾
Developer of an immune cell profiling technology designed to provide more optimal cancer treatments and groundbreaking immunotherapies to help improve cancer outcomes. The company's cell profiling technology identifies each patient's unique tumor signature and suggests key immune elements to exploit during immunotherapy, enabling physicians to better understand and tailor treatments around individual patients' disease and immune responses.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Arizona is moving
A read on the academic research around Bioinformatics in Arizona — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 196 papers.
- Mayo Clinic in Arizona75
- University of Arizona57
- Arizona State University49
- Northern Arizona University14
- University of Arizona Cancer Center5
- Gene1→10
- Genome1→7
- Metagenomics1→4
- Disease10
- Transcriptome7
- Microbiome5
- Computational biology4
- Gene4
- Immune system6
- Cancer4
- Disease4
- Biomarker3
- Mechanism (biology)3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.